Inhibition of amyloid fibrillation of lysozyme by indole derivatives - Possible mechanism of action

FEBS Journal

Volumn 274, Issue 24, 2007, Pages 6415-6425

  Morshedi, Dina ^b   Rezaei Ghaleh, Nasrollah ^b   Ebrahim Habibi, Azadeh ^b   Ahmadian, Shahin ^b   Nemat Gorgani, Mohsen ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Amyloid inhibition; Docking; Indole derivative; Lysozyme; Organic solvent

Indexed keywords

3 INDOLEMETHANOL; AMYLOID; CONGO RED; EGG WHITE; INDOLE ALDEHYDE; INDOLE DERIVATIVE; INDOLEACETIC ACID; LYSOZYME; THIOFLAVINE; TRYPTOPHAN; TRYPTOPHOL; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; FLUORESCENCE; HIGH TEMPERATURE; PH; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET RADIATION;

AMYLOID; ANIMALS; BINDING SITES; CHICKENS; CIRCULAR DICHROISM; HYDROGEN-ION CONCENTRATION; INDOLEACETIC ACIDS; INDOLES; KINETICS; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MURAMIDASE; PROTEIN BINDING; PROTEIN CONFORMATION; TEMPERATURE;

EID: 36749011905     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2007.06158.x     Document Type: Article

References (47)

1. Taylor JP, Hardy J Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296, 1991 1995.
2. Pepys MB (2001) Pathogenesis, diagnosis and treatment of systemic amyloidosis. Phil Trans R Soc Lond B Biol Sci 356, 203 210.
3. Chiti F Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75, 333 366.
4. Nelson R Eisenberg D (2006) Structural models of amyloid-like fibrils. Adv Protein Chem 73, 235 282.
5. Ferguson N, Becker J, Tidow H, Tremmel S, Sharpe TD, Krause G, Flinders J, Petrovich M, Berriman J, Oschkinat H et al. (2006) General structural motifs of amyloid protofilaments. Proc Natl Acad Sci USA 103, 16248 16253.
6. Makin OS Serpell LC (2002) Examining the structure of the mature amyloid fibril. Biochem Soc Trans 30, 521 525.
7. Sunde M Blake C (1997) The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem 50, 123 159.
8. Chamberlain AK, MacPhee CE, Zurdo J, Morozova-Roche LA, Hill HA, Dobson CM Davis JJ (2000) Ultrastructural organization of amyloid fibrils by atomic force microscopy. Biophys J 79, 3282 3293.
9. Jahn TR Radford SE (2005) The Yin and Yang of protein folding. FEBS J 272, 5962 5970.
10. Dobson CM (2003) Protein folding and misfolding. Nature 426, 884 890.
11. Masuda M, Suzuki N, Taniguchi S, Oikawa T, Nonaka T, Iwatsubo T, Hisanaga S, Goedert M Hasegawa M (2006) Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 45, 6085 6094.
12. Vieira MN, Figueroa-Villar JD, Meirelles MN, Ferreira ST De Felice FG (2006) Small molecule inhibitors of lysozyme amyloid aggregation. Cell Biochem Biophys 44, 549 553.
13. Cohen T, Frydman-Marom A, Rechter M Gazit E (2006) Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry 45, 4727 4735.
14. De Felice FG, Vieria MN, Saraiva LM, Figueroa-Villar J, Garcia-Abreu J, Liu R, Chang L, Klein WL Ferreira ST (2004) Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Aβ oligomerization. FASEB J 18, 1366 1372.
15. Cardoso I Saraiva MJ (2006) Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J 20, 234 239.
16. Chirita C, Necula M Kuret J (2004) Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43, 2879 2887.
17. Li J, Zhu M, Rajamani S, Uversky VN Fink AL (2004) Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol 11, 1513 1521.
18. Ono K Yamada M (2006) Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 97, 105 115.
19. Chiti F, Taddei N, Stefani M, Dobson CM Ramponi G (2001) Reduction of the amyloidogenicity of a protein by specific binding of ligands to the native conformation. Protein Sci 10, 879 886.
20. Soldi G, Plakoutsi G, Taddei N Chiti F (2006) Stabilization of a native protein mediated by ligand binding inhibits amyloid formation independently of the aggregation pathway. J Med Chem 49, 6057 6064.
21. Wiseman RL, Green NS Kelly JW (2005) Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis. Biochemistry 44, 9265 9274.
22. Chyan YJ, Poeggeler B, Omar RA, Chain DG, Frangione B, Ghiso J Pappolla MA (1999) Potent neuroprotective properties against the Alzheimer β-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J Biol Chem 274, 21937 21942.
23. Bendheim PE, Poeggeler B, Neria E, Ziv V, Pappolla MA Chain DG (2002) Development of indole-3-propionic acid (oxigon) for Alzheimer's disease. J Mol Neurosci 19, 213 217.
24. Zheng M, Zheng M, Ye D, Deng Y, Qiu S, Luo X, Chen K, Liu H Jiang H (2007) Indole derivatives as potent inhibitors of 5-lipoxygenase: design, synthesis, biological evaluation, and molecular modeling. Bioorg Med Chem Lett 17, 2414 2420.
25. Hsu JC, Dev A, Wing A, Brew CT, Bjeldanes LF Firestone GL (2006) Indole-3-carbinol mediated cell cycle arrest of LNCaP human prostate cancer cells requires the induced production of activated p53 tumor suppressor protein. Biochem Pharmacol 72, 1714 1723.
26. Liou JP, Mahindroo N, Chang CW, Guo FM, Lee SW, Tan UK, Yeh TK, Kuo CC, Chang YW, Lu PH et al. (2006) Structure-activity relationship studies of 3-aroylindoles as potent antimitotic agents. Chem Med Chem 1, 1106 1118.
27. Torok M, Abid M, Mhadgut SC Torok B (2006) Organofluorine inhibitors of amyloid fibrillogenesis. Biochemistry 45, 5377 5383.
28. Sanchez de Groot N, Pallares I, Aviles FX, Vendrell J Ventura S (2005) Prediction of 'hot spots' of aggregation in disease-linked polypeptides. BMC Struct Biol 30, 5 18.
29. Pawar AP, Dubay KF, Zurdo J, Chiti F, Vendruscolo M Dobson CM (2005) Prediction of 'aggregation-prone' and 'aggregation-susceptible' regions in proteins associated with neurodegenerative diseases. J Mol Biol 350, 379 392.
30. Gazit E (2002) The possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB 16, 77 83.
31. Bemporad F, Taddei N, Stefani M Chiti F (2006) Assessing the role of aromatic residues in the amyloid aggregation of human muscle acylphosphatase. Protein Sci 15, 862 870.
32. Wu C, Lei H Duan Y (2005) The role of Phe in the formation of well-ordered oligomers of amyloidogenic hexapeptide (NFGAIL) observed in molecular dynamics simulations with explicit solvent. Biophys J 88, 2897 2906.
33. De Felice FG, Houzel J, Garcia-Abreu J, Louzada PR, Afonso RC, Meirelles ML, Lent R, Neto VM Ferreira ST (2001) Inhibition of Alzheimer's disease β-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy. FASEB J 15, 1297 1299.
34. Tracz SM, Abedini A, Driscoll M Raleigh DP (2004) Role of aromatic interactions in amyloid formation by peptides derived from human amylin. Biochemistry 43, 15901 15908.
35. Arnaudov LN de Vries R (2005) Thermally induced fibrillar aggregation of hen egg white lysozyme. Biophys J 88, 515 526.
36. Malisauskas M, Darinskas A, Zamotin VV, Gharibyan A, Kostanyan IA Morozova-Roche LA (2006) Intermediate amyloid oligomers of lysozyme: is their cytotoxicity a particular case or general rule for amyloid? Biochemistry (Mosc) 71, 505 512.
37. Gharibyan AL, Zamotin V, Yanamandra K, Moskaleva OS, Margulis BA, Kostanyan IA Morozova-Roche L (2007) Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. J Mol Biol 365, 1337 1349.
38. Shinitzky M, Katchalski E, Grisaro V Sharon N (1966) Inhibition of lysozyme by imidazole and indole derivatives. Arch Biochem Biophy 116, 332 343.
39. Swan ID (1972) The inhibition of HEWL by imidazole and indole derivatives. J Mol Biol 65, 59 62.
40. Morozova-Roche LA, Zurdo J, Spencer A, Noppe W, Receveur V, Archer DB, Joniau M Dobson CM (2000) Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants. J Struct Biol 130, 339 351.
41. Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27, 570 575.
42. Fink AL Uversky VN (2004) Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim Biophys Acta 1698, 131 153.
43. Strynadka NC James MN (1991) Lysozyme revisited: crystallographic evidence for distortion of an N-acetylmuramic acid residue bound in site D. J Mol Biol 220, 401 424.
44. Cardamone M Puri NK (1992) Spectrofluorimetric assessment of the surface hydrophobicity of proteins. Biochem J 282, 589 593.
45. Nilsson MR (2004) Techniques to study amyloid fibril formation in vitro. Methods 34, 151 160.
46. Klunk WE, Pettegrew JW Abraham DJ (1989) Quantitative evaluation of Congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem 37, 1273 1281.
47. Sackett DL Wolff J (1987) Nile red as a polarity-sensitive fluorescent probe of hydrophobic protein surfaces. Anal Biochem 167, 228 234.